| Autor: |
Damjanov, Nemanja, Kirvalidze, Nana, Kurashvili, Nana, Berti, Fausto, Steiger, Matjaz, Sobierska, Joanna, Guenzi, Eric, Otto, Hendrik, Sattar, Abid, Haliduola, Halimu N., Edwald, Elin, Stroissnig, Heimo |
| Zdroj: |
Expert Opinion on Biological Therapy; August 2023, Vol. 23 Issue: 8 p781-789, 9p |
| Abstrakt: |
ABSTRACTBackgroundThis study investigated the ability of patients, naïve to adalimumab treatment and self-injection with an autoinjector (AI), to successfully self-administer AVT02, an adalimumab biosimilar, using a custom, ergonomic AI (Alvotech hf., Reykjavik, Iceland).Research design and methodsThis was a single-arm, open-label study, consisting of an 8-week active period and 48-week extension phase. Patients with moderate to severe rheumatoid arthritis (RA) self-administered 40 mg AVT02 subcutaneously via AI in the active period, followed by prefilled syringe in the extension phase. The primary endpoint was the percentage of successful self-injections up to Week 8. Usability and robustness of the AI were evaluated in the active period; safety, efficacy, pharmacokinetic and immunogenicity data were assessed throughout the study.ResultsThe AI success rate was 100%. No handling events were noted up to Week 8. Both Ctroughmeasurements and immunogenicity profile were in line with expectations from previous studies, with no unexpected safety signals.ConclusionsThis study demonstrated that AVT02-AI can be successfully and reliably used for repeated self-injections of AVT02 by moderate to severe RA patients, despite no previous experience of adalimumab self-administration. The extension phase provides long-term efficacy and safety data for AVT02 in RA.Study identifierNCT04224194 |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
